anistreplase
Sign in to saveAlso known as BRL-26921, APSAC, t-plasminogen activator, Tissue-type plasminogen activator precursor, t- PA, tPA
Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.
Research
483 papers- Pharmacology of anistreplase.Clinical cardiology · 1990
- Anistreplase: a new thrombolytic for the treatment of acute myocardial infarction.Clinical pharmacy · 1990
- Anistreplase: a novel thrombolytic agent for acute myocardial infarction.DICP : the annals of pharmacotherapy · 1990
- Alteplase and anistreplase in acute myocardial infarction.Drug and therapeutics bulletin · 1989
- An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.Journal of interventional cardiology · 1993
via PubMed
~1 min read
Article
3 sectionsContents
- Uses
- History
- References
Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.
== Uses == Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction. Early treatment gives better outcomes.
Available in 8 languages
via Wikidata sitelinks · CC0
Connections
thrombolysis
Entity
hirudin
Entity
coagulation factor X
Protein
ximelagatran
Entity
blood
Entity
medication
Entity
myocardial infarction
Entity
aspirin
Entity
digital object identifier
Entity
nucleotide
Entity
citric acid
Entity
molar mass
Entity
Q180686
Entity
CAS Registry Number
Entity
heparin
Entity
Q229883
Entity
nucleoside
Entity
Anatomical Therapeutic Chemical Classification System
Entity
pharmacokinetics
Entity
coumarin
Entity